Pubblicazioni

Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction. a subgroups analysis from the EMPHASIS-HF trial

2023 - EUROPEAN JOURNAL OF HEART FAILURE

Monzo, Luca; Girerd, Nicolas; Duarte, Kevin; Ferreira, JoÃ£o Pedro; Mcmurray, John J V; van Veldhuisen, Dirk J; Swedberg, Karl; Pocock, Stuart J; Pitt, Bertram; Zannad, Faiez

Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction. findings from the eplerenone in Patients with systolic heart failure and mild symptoms trial

2020 - JOURNAL OF HYPERTENSION

Monzo, L.; Ferreira, J. P.; Abreu, P.; Szumski, A.; Bohm, M.; McMurray, J. J. V.; Pitt, B.; Swedberg, K.; Van Veldhuisen, D. J.; Girerd, N.; Vincent, J.; Zannad, F.; Rossignol, P.

Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension

2015 - INTERNATIONAL JOURNAL OF CARDIOLOGY

Pelliccia, Francesco; Rosano, Giuseppe; Patti, Giuseppe; Volterrani, Maurizio; Greco, Cesare; Gaudio, Carlo

Safety profile of mineralocorticoid receptor antagonists. spironolactone and eplerenone

2015 - INTERNATIONAL JOURNAL OF CARDIOLOGY

Lainscak, Mitja; Pelliccia, Francesco; Rosano, Giuseppe; Vitale, Cristiana; Schiariti, Michele Salvatore Maria; Greco, Cesare; Speziale, Giuseppe; Gaudio, Carlo

Mineralocorticoid receptor antagonists, a class beyond spironolactone. focus on the special pharmacologic properties of eplerenone

2015 - INTERNATIONAL JOURNAL OF CARDIOLOGY

Seferovic, Petar M; Pelliccia, Francesco; Zivkovic, Ivana; Ristic, Arsen; Lalic, Nebojsa; Seferovic, Jelena; Simeunovic, Dejan; Milinkovic, Ivan; Rosano, Giuseppe